A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (NCT06745323)

🧪 Interventions in This Study

• Tarlatamab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (78 Sites)

Showing the first 25 of 78 sites.

• University of California Los Angeles — Los Angeles, California
• Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut — Plainville, Connecticut
• AdventHealth Hematology and Oncology — Orlando, Florida
• City of Hope Chicago — Rockford, Illinois
• Health Partners Cancer Center at Regions Hospital — Saint Paul, Minnesota
• New York Oncology Hematology PC — Albany, New York
• Duke University — Durham, North Carolina
• FirstHealth Cancer Center — Pinehurst, North Carolina
• Guthrie Medical Group — Sayre, Pennsylvania
• Tennessee Oncology PLLC - Chattanooga — Chattanooga, Tennessee
• Tennessee Oncology, PLLC — Nashville, Tennessee
• Virginia Cancer Specialists PC — Fairfax, Virginia
• Fundacion Respirar — Ciudad Autonoma de Buenos Aires, Buenos Aires
• Instituto de Investigaciones clinicas de Mar del Plata — Mar del Plata, Buenos Aires
• Monash Medical Centre — Clayton, Victoria
• Austin Health, Austin Hospital — Heidelberg, Victoria
• Grand Hopital de Charleroi - Site des Viviers — Charleroi,
• Universitair Ziekenhuis Antwerpen — Edegem,
• Jessa Ziekenhuis - Campus Virga Jesse — Hasselt,
• Liga Norte-Riograndense Contra O Cancer — Natal, Rio Grande do Norte
• Hospital de Clinicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
• Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul — Porto Alegre, Rio Grande do Sul
• Cipo - Centro Integrado de Pesquisa em Oncologia — Porto Alegre, Rio Grande do Sul
• Hospital de Amor — Barretos, São Paulo
• Hospital de Base de Sao Jose do Rio Preto — São José do Rio Preto, São Paulo

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Small Cell Lung Cancer (SCLC)

• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Mobile, Alabama
• Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer — Fayetteville, Arkansas
• Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer — Chicago, Illinois
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — Duarte, California
• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy — Mobile, Alabama

Explore by condition: All Small Cell Lung Cancer (SCLC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.